Xilio Therapeutics, Inc.

Xilio Chief Executive Officer Rene Russo, Pharm.D., will share her perspectives and industry experiences about elevating the patient voice during a Leadership Keynote conversation at this year’s Chief Patient Officer Summit hosted by Dynamic Global Events (DGE) on Tuesday, July 16 at 1:25 PM ET. This event is the industry’s largest forum for revolutionizing patient engagement strategy and emphasizes the understanding of patient community influence. Learn more and register: https://lnkd.in/dAyD4uk

Today, we announced the appointment of Aoife Brennan, M.D., and James Shannon, M.D., to our board of directors. Dr. Brennan and Dr. Shannon are well-accomplished industry veterans who bring deep leadership and drug development experience spanning all stages of drug development. We look forward to utilizing their expertise as we advance our pipeline of novel, tumor-activated I-O therapies. Read more: https://lnkd.in/eR3tF2EK

Investment Reports latest “New Era of Life Sciences” report in Newsweek recently highlighted innovations in immunotherapy, including Xilio’s geographic precision medicines. Our tumor-selective immunotherapies are designed to focus the immune system's tumor-destroying effect locally in tumor tissue but not in healthy tissues – by localizing activity to the tumor, we hope to overcome the toxicities of prior generations of immunotherapies. Read the interview with our President and CEO, Dr. Rene Russo here: https://lnkd.in/eDAe57en

Today, we reported our Q1 2024 financial results and highlighted continued progress across our pipeline of tumor-activated molecules. Read our press release to learn more: https://lnkd.in/egSWGTiz

We're pleased to have shared preclinical data from Xilio's first bispecific program, XTX501, a tumor-activated PD-1/IL-2 bispecific molecule at #AACR24. The data presented suggest that XTX501 has the potential to improve upon the anti-tumor activity of the existing PD-1/PD-L1 immunotherapies while maintaining a favorable therapeutic index. Discover more from the poster below. https://lnkd.in/eJsrHCmk

At #AACR24, Xilio will share preclinical data from our first bispecific program, XTX501, a tumor-activated PD-1/IL-2 bispecific development candidate during this Sunday’s poster presentation session at 1:30 pm PT. Learn more about our research at https://xiliotx.com/.  #cancerresearch #Xiliotx

In addition to our exclusive license and collaboration agreement with Gilead announced earlier today, we also announced a private placement equity financing with existing and new investors and other corporate updates. Learn more in the release below and tune into the webcast today at 8:00 a.m. ET for more details. https://lnkd.in/eS468sg7

Today, we’re pleased to share that we’ve entered into an exclusive license agreement with Gilead Sciences, Inc. to develop and commercialize our tumor-activated IL-12 program, including XTX301, our Phase 1 IL-12 molecule with the potential to treat a broad range of cancers Learn more in the release below. https://lnkd.in/e8kS5Sxx

Today, we highlighted advances across our clinical pipeline, including encouraging preliminary Phase 1 safety data for XTX301, our tumor-activated IL-12, which further validate the promise of our tumor-activated I-O pipeline. Read our press release to learn more: https://lnkd.in/e7zht9yk #xiliotx #cancerresearch #immunooncology

We’re pleased to share that preclinical research for XTX101, our tumor-activated, Fc-enhanced anti-CTLA-4, was published recently in the Journal for ImmunoTherapy of Cancer. The publication describes the discovery of XTX101 and demonstrates preclinically that XTX101 is designed to retain the full potency of an Fc-enhanced CTLA-4 antagonist within the tumor microenvironment while minimizing the activity in non-tumor tissue, further supporting the broad potential of XTX101 in solid tumors, particularly in combinations. Congratulations to all the authors for their contributions to the research and article. Read the article here: https://lnkd.in/eQZGN8xs #Xiliotx  #JITC #CTLA4